PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 159 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 2.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $65,000 | +8.3% | 1,395 | -12.3% | 0.00% | – |
| Q3 2019 | $60,000 | -27.7% | 1,591 | -16.5% | 0.00% | -100.0% |
| Q2 2019 | $83,000 | 0.0% | 1,905 | -13.4% | 0.00% | 0.0% |
| Q1 2019 | $83,000 | -20.2% | 2,201 | -10.1% | 0.00% | 0.0% |
| Q4 2018 | $104,000 | -4.6% | 2,449 | +10.0% | 0.00% | 0.0% |
| Q3 2018 | $109,000 | +91.2% | 2,226 | +26.3% | 0.00% | 0.0% |
| Q2 2018 | $57,000 | +3.6% | 1,763 | +1.2% | 0.00% | 0.0% |
| Q1 2018 | $55,000 | -28.6% | 1,742 | +3.2% | 0.00% | 0.0% |
| Q4 2017 | $77,000 | +10.0% | 1,688 | -9.9% | 0.00% | 0.0% |
| Q3 2017 | $70,000 | -20.5% | 1,874 | +2.3% | 0.00% | -50.0% |
| Q2 2017 | $88,000 | +31.3% | 1,832 | +27.0% | 0.00% | +100.0% |
| Q1 2017 | $67,000 | +52.3% | 1,443 | +5.1% | 0.00% | 0.0% |
| Q4 2016 | $44,000 | -33.3% | 1,373 | -28.9% | 0.00% | -50.0% |
| Q3 2016 | $66,000 | +20.0% | 1,930 | +13.7% | 0.00% | +100.0% |
| Q2 2016 | $55,000 | – | 1,697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |